Changes in screening, prognosis and therapy for esophageal adenocarcinoma in Barrett's esophagus

Current Opinion in Gastroenterology

Volumn 25, Issue 4, 2009, Pages 358-365

  Tomizawa, Yutaka ^a   Wang, Kenneth K ^a,b  

^a MAYO CLINIC   (United States)

^b ST MARY S HOSPITAL   (United States)

Author keywords

Esophageal capsule endoscopy; Fluorescent in situ hybridization; Narrow band imaging; Photodynamic therapy; Radiofrequency ablation

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D; PHOTOFRIN; PHOTOSENSITIZING AGENT; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR;

ALLELE; BARRETT ESOPHAGUS; CANCER SCREENING; CANCER THERAPY; CHROMOSOME; CHROMOSOME ABERRATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; ENDOSCOPIC SURGERY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL REFLUX; GOLD STANDARD; HEALTH CARE COST; HETEROZYGOSITY LOSS; HUMAN; NARROW BAND IMAGING; PHOTODYNAMIC THERAPY; POLYMERASE CHAIN REACTION; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY, NEEDLE; CAPSULE ENDOSCOPY; CATHETER ABLATION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MASS SCREENING; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK ASSESSMENT; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TREATMENT OUTCOME;

EID: 68049106293     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832c148f     Document Type: Review

References (54)

1. Spechler S. Barrett's esophagus. N Engl J Med 2002; 346:836-842.
2. Haggitt R. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25:982-993.
3. Haggitt R. Pathology of Barrett's esophagus. J Gastrointest Surg 2000; 4:117-118.
4. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. Am J Gastroenterol 2006; 101:2457-2462. (Pubitemid 44665238)
5. Brown L, Devesa S, Chow WH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst 2008; 100:1184-1187. This epidemiologic study showed rapid increases in the incidence of esophageal adenocarcinoma not only among white men but also among white women.
6. Drewitz D, Sampliner R, Garewal H. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215. (Pubitemid 27076463)
7. O'Connor J, Falk G, Richter J. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999; 94:2037-2042. (Pubitemid 29374529)
8. Shaheen N, Crosby M, Bozymski E, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119:333-338.
9. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98:1931-1939. (Pubitemid 37185786)
10. Shaheen N. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005; 128:1554-1566. (Pubitemid 40692552)
11. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3:543-552. (Pubitemid 40824747)
12. Liu L, Hofstetter W, Rashid A, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 2005; 29:1079-1085.
13. Birkmeyer J, Siewers A, Finlayson E, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128-1137. (Pubitemid 34984604)
14. Finlayson E, Goodney P, Birkmeyer J. Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg 2003; 138:721-725. (Pubitemid 36858150)
15. Wang K, Sampliner R. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103:788-797. This is the most recent guideline in screening, surveillance and therapy of Barrett's esophagus.
16. Chak A, Faulx A, Eng C, et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer 2006; 107:2160-2166. (Pubitemid 44665649)
17. Ruol A, Parenti A, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer 2000; 88:2520-2528. (Pubitemid 30331958)
18. Pera M. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res 2000; 155:1-14.
19. Mueller J, Werner M, Siewert J. Malignant progression in Barrett's esophagus: pathology and molecular biology. Recent Results Cancer Res 2000; 155:29-41.
20. Eloubeidi M, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999; 94:937-943. (Pubitemid 29173605)
21. Kara MA, Ennahachi M, Fockens P, et al. Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett's esophagus by using narrow band imaging. Gastrointest Endosc 2006; 64:155-166. (Pubitemid 44062482)
22. Sharma P, Bansal A, Mathur S, et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc 2006; 64:167-175. (Pubitemid 44081900)
23. Shaheen N, Ransohoff D. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer, scientific review. JAMA 2002; 287:1972-1981. (Pubitemid 34326418)
24. Lin O, Schembre D, Mergener K, et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett's esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc 2007; 65:577-583. (Pubitemid 46454272)
25. Sharma P, Wani S, Rastogi A, et al. The diagnostic accuracy of esophageal capsule endoscopy in patients with gastroesophageal reflux disease and Barrett's esophagus: a blinded, prospective study. Am J Gastroenterol 2008; 103:525-532. In this prospective, blinded study, the sensitivity, specificity, positive predictive value and negative predictive value of esophageal capsule endoscopy for Barrett's esophagus in GERD patients were 67, 87, 60 and 90%, respectively.
26. Ramirez F, Shaukat M, Young M, et al. Feasibility and safety of string, wireless capsule endoscopy in the diagnosis of Barrett's esophagus. Gastrointest Endosc 2005; 61:741-746. (Pubitemid 40603049)
27. Ramirez F, Akins R, Shaukat M. Screening of Barrett's esophagus with stringcapsule endoscopy: a prospective blinded study of 100 consecutive patients using histology as the criterion standard. Gastrointest Endosc 2008; 68:25-31. In this prospective, blinded study of patients for screening of Barrett's esophagus, string capsule endoscopy had an acceptable sensitivity, specificity and negative predictive value when compared with EGD using histology as the criterion standard.
28. Rubenstein J, Inadomi J, Brill J, et al. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol 2007; 5:312-318. (Pubitemid 46401523)
29. Gerson L, Lin O. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol 2007; 5:319-325. (Pubitemid 46401528)
30. Jankowski J, Wright N, Meltzer S, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999; 154:965-973. (Pubitemid 29169728)
31. Fitzgerald RC. Complex diseases in gastroenterology and hepatology: GERD, Barrett's, and esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2005; 3:529-537.
32. Walch A, Zitzelsberger H, Bruch J, et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 2000; 156:555-566. (Pubitemid 30643811)
33. Riegman P, Vissers K, Alers J, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001; 61:3164-3170. (Pubitemid 32691970)
34. Atherfold P, Jankowski J. Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol 2006; 20:813-827.
35. Younes M, Lebovitz R, Lechago L, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105:1637-1642. (Pubitemid 2024863)
36. Reid B, Prevo L, Galipeau P, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96:2839-2848.
37. Bian Y, Osterheld M, Fontolliet C, et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002; 122:1113-1121. (Pubitemid 34267292)
38. Hardie L, Darnton S, Wallis Y, et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005; 217:221-230. (Pubitemid 40023121)
39. Casson A, Zheng Z, Evans S, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 2005; 104:730-739. (Pubitemid 41113671)
40. Maley C, Galipeau P, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004; 64:7629-7633. (Pubitemid 39372110)
41. Chao D, Sanchez C, Galipeau P, et al. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res 2008; 14:6988-6995. This study of 276 patients without detectable aneuploidy reported that bi-allelic inactivation of p53 was associated with the future development of EAC.
42. Halling K, Kipp B. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol 2007; 38:1137-1144. (Pubitemid 47058172)
43. Brankley S, Wang K, Harwood A, et al. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. 2006; 8:260-267.
44. Barr Fritcher E, Brankley S, Kipp B, et al. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol 2008; 39:1128-1135. This study compared the utility of FISH probe set to DNA ploidy analysis with digital image analysis (DIA) for the detection of dysplasia and EAC in patients undergoing endoscopic surveillance. FISHwas more sensitive than DIA for LGD,HGDand EAC and all patients with a polysomic FISH result hadHGD and/or EAC within 6 months.
45. Prasad G, Wang K, Buttar N, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in barrett's Esophagus. Gastroenterology 2007; 132:1226-1233. (Pubitemid 46627583)
46. Petersen B, Chuttani R, Croffie J, et al. Photodynamic therapy for gastrointestinal disease. Gastrointest Endosc 2006; 63:927-932.
47. Overholt B, Panjehpour M, Haydek J. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49:1-7. (Pubitemid 29076815)
48. Overholt B, Lightdale C, Wang K, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005; 62:488-498. (Pubitemid 41383764)
49. Overholt B, Wang K, Burdick J, et al. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007; 66:460-468. (Pubitemid 47304412)
50. Rodriguez S, Adler D, Chand B, et al. Mucosal ablation devices. Gastrointest Endosc 2008; 68:1031-1042.
51. Sharma V, Wang K, Overholt B, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65:185-195. (Pubitemid 46157125)
52. Fleischer D, Overholt B, Sharma V, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68:867-876. This is a multicenter, prospective clinical trial with 2.5-year follow-up to assess the long-term safety and efficacy of circumferential ablation for Barrett's esophagus. It reported 60 of 61 patients with intestinal metaplasia achieved complete remissions.
53. Ganz R, Overholt B, Sharma V, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc 2008; 68:35-40. In this multicenter study of RFA for 92 patients with HGD with a mean follow-up of 12 months, it reported that complete elimination of HGD was 90.2% of patients. (Pubitemid 351902211)
54. Bronner M, Overholt B, Taylor S, et al. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology 2009; 136:56-64. This study assessed histologically the prevalence of squamous overgrowth and degree of subsquamous dysplasia or cancer in patients with HGD treated with PDT trial. It reported the highest grade of neoplasia was not found beneath squamous mucosa in any patients and there was no significant difference in squamous overgrowth between PDT-group and non PDT-group.